IBD and cannabis: a new review study

This study reviewed published articles about cannabis use in IBD (Inflammatory Bowel Disease) patients. They focused on treatment, remission, and symptom relief. It was published in the journal Cureus in March 2023.

29 studies published between 2012 and 2022 were included in the review. The studies reviewed included some randomized controlled trials (RCT) and preclinical in vivo research studies.

The authors state that most of the studies show positive results on most of the measurement criteria used. The studies looked at THC, CBD, CBN, CBG, and a few other cannabinoids.

However, they also note that the study designs, administration methods, dosages, duration of treatment, and other factors differ significantly among studies. As such, they weren't able to make any "outcome generalizability" and called for more clinical research in those areas.

Authors' conclusions:

the studies’ significant findings and points of convergence demonstrated general well-being improvement in IBD patients, as well as the quality of life improvement, deemed statistically significant

cannabinoid usage in IBD treatment comes with promising results as reported in the majority of the selected studies which reported reduced clinical complications which were assessed using Mayo scores, Crohn’s Disease Activity Index (CDAI) score, weight gain, enhanced patient health perception, Lichtiger Index and Harvey-Bradshaw Index or general wellbeing.


The full text article is here at PubMed Central.